TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03510533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of the rates of the autoantibodies directed against the neuropeptides (ghrelin and alpha-MSH) controlling involved in food intake regulation
Description: blood samples (12ml) and stool samples (30g) collections

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of the rates of the autoantibodies directed against the neuropeptides (ghrelin and alpha-MSH) controlling involved in food intake regulation
Description: blood samples (12ml) and stool samples (30g) collections
Study: NCT04037644

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid loading with Albumin
Description: Fluid loading with 200 ml of 4% Albumin to reverse acute circulatory failure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluid loading with Ringer Lactate
Description: Fluid loading with 5 ml per kg of actual body weight to reverse acute circulatory failure
Study: NCT02816112

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Antibiotic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neupogen
Description: Granulocyte-colony stimulating factor
Study: NCT03990038

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous perineural infusion of ropivacaine 0.2% 5 ml/h for 48 h
Description: Group C receive the intervention Group U receives the placebo See arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended Release Capsule
Description: Group C receives a placebo for extended release hydromorphone Group U receives Hydromorph Contin 3 mg PO BID~See arm description
Study: NCT04313452

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: the effect of Mediterranean diet on insulin sensitivity among obese children and adolescents aged
Description: to find the effect of Mediterranean diet on insulin resistance among obese children and adolescents aged 10-16 years with insulin resistance compared to the regular diet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: the effect of Mediterranean diet on insulin sensitivity among obese children and adolescents aged
Description: to find the effect of Mediterranean diet on insulin resistance among obese children and adolescents aged 10-16 years with insulin resistance compared to the regular diet
Study: NCT02124460

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching
Description: Parent/child duos enrolled in the intervention group will participate in a total of six visits with a trained health coach. During these visits, the health coach will coach the parent/child duos on improving obesity-related behaviors .~The health coach will also help the family identify supports to assist with behavior change; discuss family health habits and the home environment; and review and encourage use of materials related to both specific target behaviors and available resources in the community.~Following the first call with the health coach, parents will receive semi-weekly text messages designed by the study team. The messages will alternate in structure between 2 types of messages; 1) skills training messages will deliver tips and motivational messages to help their child practice the study's goals and 2) self monitoring messages will ask parents to respond to the message and track health behaviors important to this study.
Study: NCT05367674

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Summer Harvest Adventure
Description: Biobehavioral intervention focusing on nutrition and lifestyle behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: My Summer Plate (MSP)
Description: My Summer Plate (MSP)
Study: NCT03750656

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyoscyamine
Description: Patients will be randomized to receive hyoscyamine for lower urinary tract symptoms are placement of ureteral stent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: Patients will be randomized to receive tamsulosin for lower urinary tract symptoms are placement of ureteral stent
Study: NCT01149603

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartMate II Ventricular Assist Device
Description: The HeartMate II Left Ventricular Assist Device has been approved by the FDA for use in bridge-to-transplant therapy and destination therapy for patients with endstage heart failure.
Study: NCT01096056

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine GSK2186877A formulation 1
Description: Intramuscular administration, 2 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine GSK2186877A formulation 2
Description: Intramuscular administration, 1 dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix
Description: Intramuscular administration, 1 dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix
Description: Intramuscular administration, 1 dose
Study: NCT00198874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Family and Cognitive-Behavioral Therapy
Description: The family therapy component of IFCBT includes engagement, active treatment, and maintenance phases. The cognitive program focuses on harmful effects of drugs and strategies to better manage drug abuse risks. The cognitive-behavioral program introduces youths to problem-solving behavior change principles and study skills to promote school achievement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Family and Cognitive-Behavioral Therapy
Description: The family therapy component of IFCBT includes engagement, active treatment, and maintenance phases. The cognitive program focuses on harmful effects of drugs and strategies to better manage drug abuse risks. The cognitive-behavioral program introduces youths to problem-solving behavior change principles and study skills to promote school achievement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Family and Cognitive-Behavioral Therapy
Description: The family therapy component of IFCBT includes engagement, active treatment, and maintenance phases. The cognitive program focuses on harmful effects of drugs and strategies to better manage drug abuse risks. The cognitive-behavioral program introduces youths to problem-solving behavior change principles and study skills to promote school achievement.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Drug education curriculum was delivered to participants assigned to this condition.
Study: NCT03571243

Intervention type: OTHER
Intervention: no intervention
Description: observational study

Intervention type: OTHER
Intervention: no intervention
Description: observational study
Study: NCT00421902

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Patients will be have acupuncture (with electro stimulation)
Study: NCT02594176

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLEXISEQ®
Description: applicable gel

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: applicable gel
Study: NCT03568162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISB 830 - Part 1 Group 1
Description: Subcutaneous injection (SC) every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISB 830 - Part 1 Group 2
Description: Subcutaneous injection (SC) every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISB 830 - Part 1 Group 3
Description: Subcutaneous injection (SC) every 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Part 1 Group 4
Description: Subcutaneous injection (SC) every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISB 830 - Part 2 Group 5
Description: Subcutaneous injection (SC) every 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Part 2 Group 6
Description: Subcutaneous injection (SC) every 2 weeks
Study: NCT01793272

Intervention type: OTHER
Group type: OTHER
Intervention: effect of pentoxifylline on ICSI outcome
Description: semen processing with pentoxifylline prior to ICSI
Study: NCT02454907

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Communication with the clinic
Description: Over the course of the study, subjects will receive brief periodic communications on their cellular phone from the doctor's office.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication with the clinic
Description: Over the course of the study, subjects will receive brief periodic communications on their cellular phone from the doctor's office.
Study: NCT03419520

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional counseling
Description: Schoolchildren, parents and teachers from intervention schools, will regularly receive nutrition and healthy lifestyle guidelines performed by nutritionists. Moreover, workshops aimed to reinforce the healthy habits will also be held along the study.
Study: NCT02484183

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bubble continuous positive airway pressure (CPAP)
Description: This study will use an Airsep® oxygen concentrator and a Fisher \& Paykel Bubble CPAP (bCPAP) system to deliver bCPAP. The Airsep® machine is connected to the Fischer \& Paykel Bubble CPAP system and the CPAP delivers pressure and oxygen to the patient with appropriately sized masks and tubing. The Fischer \& Paykel Bubble CPAP system can deliver up to 10 centimeters (cm) water (H20) pressure. Since an oxygen concentrator is being used as the flow driver of this bubble CPAP system patients receiving CPAP will therefore also be receiving 6-8 liters per minute (LPM) of concentrated oxygen flow. Per manufacturer specifications the Airsep oxygen concentrator delivers 90-97% fractional inspired oxygen concentration at the 6-8 LPM flows required to generate 4-10 cm H20 pressure.
Study: NCT04523948

Intervention type: BEHAVIORAL
Intervention: Behavioral and pharmacological support to reduce combustible tobacco use.
Description: Behavioral and pharmacological support to reduce combustible tobacco use.

Intervention type: BEHAVIORAL
Intervention: Behavioral and pharmacological support to reduce combustible tobacco use.
Description: Behavioral and pharmacological support to reduce combustible tobacco use.

Intervention type: BEHAVIORAL
Intervention: Behavioral and pharmacological support to reduce combustible tobacco use.
Description: Behavioral and pharmacological support to reduce combustible tobacco use.

Intervention type: BEHAVIORAL
Intervention: Behavioral and pharmacological support to reduce combustible tobacco use.
Description: Behavioral and pharmacological support to reduce combustible tobacco use.
Study: NCT01180374

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (about a quarter spoon of alcohol with no CBD).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (about a quarter spoon of alcohol with no CBD).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (about a quarter spoon of alcohol with no THC) given intravenously over 20 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (about a quarter spoon of alcohol with no THC) given intravenously over 20 minutes.
Study: NCT04523948

Intervention type: BEHAVIORAL
Intervention: Behavioral and pharmacological support to reduce combustible tobacco use.
Description: Behavioral and pharmacological support to reduce combustible tobacco use.
Study: NCT03728530

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep Breathing exercises
Description: In pursed lip exercise subject was guided to inhale through nose with mouth closed and exhale through pressed lips (pursed lips).~In Diaphragmatic breathing subject was instructed to place his one hand below the rib cage and the other hand on chest. The patient inhaled slowly so that stomach moves out against the hand. Tighten the stomach muscle while exhaling through pursed lip.~In powered breathing subject was to inhale and exhale forcefully with some movements like subject was instructed to inhale forcefully while moving his hands upward and exhale forcefully while moving hands downward.~These three exercise techniques were advised to each subject of experimental group. They have to practice these exercises 3-4 times a day with 10 repetitions each. These exercises can be performed in sitting position or in supine lying position. Subject can adopt any position in which he feels comfortable.
Study: NCT03419611

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-Modal
Description: Intervention combining speech sound practice, AAC and receptive practice on a set of individually determined words. Words are selected based on phonological properties. Delivered 3 times per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-Modal
Description: Intervention combining speech sound practice, AAC and receptive practice on a set of individually determined words. Words are selected based on phonological properties. Delivered 3 times per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-Modal
Description: Intervention combining speech sound practice, AAC and receptive practice on a set of individually determined words. Words are selected based on phonological properties. Delivered 3 times per week.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: Teacher provided with word list and teacher intervening as usual.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Teacher provided with word list and teacher intervening as usual.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Teacher provided with word list and teacher intervening as usual.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Multi-Modal
Description: Intervention combining speech sound practice, AAC and receptive practice on a set of individually determined words. Words are selected based on phonological properties. Delivered 5 times per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Multi-Modal
Description: Intervention combining speech sound practice, AAC and receptive practice on a set of individually determined words. Words are selected based on phonological properties. Delivered 5 times per week.
Study: NCT04140838

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Description: Group treatment protocol of 8 weekly 90 minute sessions. Session 1: Presentation of the general concept of ACT therapy. Session 2: Value analysis I. Session 3: Value analysis II. Session 4: Value analysis III. Session 5: Values and feelings. Session 6: Taking a direction. Session 7: Dare and change. Session 8: Ready to act with ACT.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Therapy for Depression (BATD)
Description: Group treatment protocol of 8 weekly 90 minute sessions. Session 1: Collection of information regarding areas of activity and interaction contexts.~Session 2: Identification of information related to depressive behaviours. Session 3 Obtaining complementary information regarding the characteristics of the history of patient interactions and any contexts.~Session 4: Explanation of the hypotheses of problematic behaviour, its maintenance and change throughout the intervention.~Session 5: Once the 10 target activities have been identified, a record is made to track and their progress weekly.~Session 6: Discussion of what was obtained from the records in general and of the satisfaction obtained, and explanation of the contexts and reinforcers.~Session 7: Psycho-education Session 8: New behaviours, the goals achieved and the maintenance of the weekly activity are inquired about.
Study: NCT04393623

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Reappraisal
Description: This cognitive reappraisal microintervention lasts 45-60 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: This psychoeducational microintervention lasts 45-60 minutes.
Study: NCT02176057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Study: NCT04140838

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual (TAU)
Description: Standard pharmacological treatment usually provided to patients suffering chronic pain and mild-moderate depression.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual (TAU)
Description: Standard pharmacological treatment usually provided to patients suffering chronic pain and mild-moderate depression.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Standard pharmacological treatment usually provided to patients suffering chronic pain and mild-moderate depression.
Study: NCT03009409

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Injectable Solution
Description: Once IV access has been obtained and a facemask has been applied for pre-oxygenation, the loading dose (0.25 mg/kg) of the study drug will be given over 60 seconds and the fixed infusion (5 mcg/kg/min to a maximum of 60 mg/hour) will be initiated by the anesthetist through the pump interface.~The study drug will be infused at a constant rate of 5 mcg/kg/min throughout the maintenance phase, until the end of the procedure (last suture), up to a maximum cumulative dose of 100 mg. If at any point the anesthesiologist feels that it is clinically necessary to reduce the amount of study drug infusion rate, they may opt to reduce the infusion rate by 50% (to 2.5 mcg/kg/min), or stop the infusion entirely.
Study: NCT02329795

Intervention type: RADIATION
Intervention: Radiotherapy
Description: 60 Gy in 30 fractions, 5 days a week, modulated arc therapy.

Intervention type: DRUG
Intervention: Temozolomide
Description: Concomitant: 75 mg/m2 5 days a week from start of radiotherapy. Adjuvant: 150/200 mg/m2 in 5 days per 28 days in 6 months.
Study: NCT04087863

Intervention type: OTHER
Intervention: Not applicable(observational study)
Description: Not applicable(observational study)
Study: NCT02157363

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repositioning

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single positioning
Study: NCT02751892

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active lifestyle programme
Description: The intervention is an activity lifestyle programme to increase physical activity behaviour post-intervention and to facilitate behaviour change maintenance at 3 months post-intervention.
Study: NCT00250705

Intervention type: DRUG
Group type: OTHER
Intervention: Aripiprazole
Description: The initial dose depending on the weight of the patient will be as follows: \< 25 kg = 1 mg/d; 25-50 kg = 2 mg/d; 50-70 kg = 5 mg/d; \> 70 kg = 10 mg/d (Data on File, 2003, Bristol-Myers Squibb). Thereafter the dose will be flexible based on response and tolerance for the duration of the 6 week study. All subjects initially received either a 5 or 10 mg/d (7.0 ± 2.6 mg/d) dose of aripiprazole. Thereafter the dose was individualized based on response and tolerance. Maximum dose was 20 mg.
Study: NCT03846063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation program
Description: The duration of the program is 12 weeks. Patients start the program within 7 days after of the surgery. Patients perform exercises independently at home using the tablet PC for instructions. The program includes strengthening and walking exercises based on increasing the muscle force, balance, and functionality. The exercises comprise movements that train abductors, flexors, and extensors of the affected hip. The content of the program is based on previous research and on guidelines from the American Association of Orthopaedic Surgeons. For the rest, the program is designed in line with the most recent guidelines from the Royal Dutch Society for Physical Therapy. Patients are asked to exercise at least 5 days a week, with rest days on Thursday and Sunday. Strengthening exercises will be performed 3 times a week. The instructions for the exercises will be provided by videos on the tablet PC, which patients have to imitate.
Study: NCT01325038

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Isometric exercise
Description: Isometric exercise several times/week for three months

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Isometric exercise
Description: Isometric exercise several times/week for three months
Study: NCT01964872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38877618: Part 1a
Description: Single ascending dose administered orally in liquid formulation (Formulation A). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38877618: Part 1b
Description: Single dose administered orally in capsule formulation (Formulation B). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38877618: Part 1c (optional)
Description: Single dose administered orally in an alternative capsule formulation (Formulation C). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
Study: NCT04418154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride
Description: Take epirubicin hydrochloride (90mg/m2, d1) every 14 days as one cycle for 4 cycles with cyclophosphamide, followed by nanoparticlealbumin-bound paclitaxel and Toripalimab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Take cyclophosphamide (600mg/m2, d1) every 14 days as one cycle for 4 cycles with epirubicin hydrochloride, followed by nanoparticlealbumin-bound paclitaxel and Toripalimab.
Study: NCT01964872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38877618: Part 2
Description: Single ascending dose administered orally in the formulation selected based on Parts 1a, 1b, and 1c (if applicable). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38877618: Part 3
Description: Multiple ascending dose and formulation determined in Part 2 (not to exceed 600 mg) administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38877618: Part 4 (optional)
Description: Single dose and formulation as determined in Part 3 administered orally in older healthy male participant cohort.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Parts 1a, 2, 3, and 4 (optional)
Description: Administered orally matched to study drug
Study: NCT02332005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diepalrestat choline
Description: aldose reductase inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diepalrestat choline
Description: aldose reductase inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01812473

Intervention type: OTHER
Intervention: Blood sampling
Description: During the treatment of voriconazole, at steady plasma concentrations of voriconazole, one plasma sample and one serum sample are taken.